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Abstract
Allopurinol, an inhibitor of xanthine oxidase, has been used in clinical trials of patients with
cardiovascular and chronic kidney disease. These are two pathologies with extensive links
to hypoxia and activation of the transcription factor hypoxia inducible factor (HIF) family.
Here we analysed the effects of allopurinol treatment in two different cellular models, and
their response to hypoxia. We explored the dose-dependent effect of allopurinol on Human
Foreskin Fibroblasts (HFF) and Human Umbilical Vein Endothelial Cells (HUVEC) under
hypoxia and normoxia. Under normoxia and hypoxia, high dose allopurinol reduced the ac-
cumulation of HIF-1α protein in HFF and HUVEC cells. Allopurinol had only marginal effects
on HIF-1αmRNA level in both cellular systems. Interestingly, allopurinol effects over the
HIF system were independent of prolyl-hydroxylase activity. Finally, allopurinol treatment
reduced angiogenesis traits in HUVEC cells in an in vitro model. Taken together these re-
sults indicate that high doses of allopurinol inhibits the HIF system and pro-angiogenic traits
in cells.
Introduction
Allopurinol is an inhibitor of xanthine oxidase (XO) that has been in clinical use for the treat-
ment of gout for over 50 years [1]. XO is an enzyme responsible for the successive oxidation of
hypoxanthine and xanthine, resulting in the production of uric acid, the end-product of the pu-
rine catabolic pathway. A by-product of XO action in these reactions is the generation of reac-
tive oxygen species (ROS) such as superoxide anion (O2
-) and Hydrogen Peroxide (H2O2)
from molecular oxygen [2, 3]. Therefore, the inhibition of XO by allopurinol has been hypothe-
sised as a possible “oxygen-sparing” mechanism, which may be beneficial in patients with
chronic hypoxia [4]. In addition to blocking uric acid production, inhibition of XO also leads
to an increase in hypoxanthine and xanthine. While xanthine cannot be converted to purines,
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hypoxanthine can be converted to the purine ribonucleotides, adenosine and guanosine mono-
phosphates [5]. Alteration of the levels of these ribotides maycause feedback inhibition of ami-
dophosphoribosyl transferase, the first and rate-limiting enzyme of purine biosynthesis [6]. In
addition, antioxidant or non-XO-related activities of allopurinol have been detected through
dose-dependent experiments [7, 8].
The apparent beneficial role of XO inhibitors on chronic heart failure patients could be due
to their ability to consistently improve endothelial dysfunction by reducing oxidative stress,
rather than urate reduction per se [9, 10]. Clinical studies have shown that allopurinol can treat
chronic heart failure, due to its inhibition of XO through improvements in peripheral vasodila-
tor capacity and blood flow rather than a urate-lowering effect [11]. Other clinic trials show
that allopurinol has a beneficial effect on Chronic Kidney Disease and inflammatory indices
such as C-reactive protein, a downstream marker of post NF-κB activation [12]. The molecular
mechanisms of allopurinol in cardiovascular disease and kidney disease are still not fully un-
derstood. The potential effects of allopurinol at the cellular level are various and possibly
dose dependent.
Here, the possibility of allopurinol’s actions as an oxygen-sparing agent in hypoxia, was in-
vestigated. Human Umbilical Vein Endothelial Cells (HUVECs) and Human Foreskin Fibro-
blasts (HFFs) were used to investigate endothelial cells response to hypoxia and to help
understand the mechanism of allopurinol in vitro. Analysis of HIF subunits and its targets
were analysed in response to increasing doses of Allopurinol in normoxia and hypoxia. Finally,
allopurinol effects on pro-angiogenic responses were analysed in a model of in vitro endothelial
tube formation. Allopurinol produced dose dependent effects on HIF subunit levels and in
some of its targets and resulted in reduced levels of pro-angiogenic features in vitro.
Materials and Methods
Cell culture
Human Umbilical Vein Endothelial Cells (HUVEC) (Gibco) were maintained in Medium
200 (Gibco) supplemented with Low Serum Growth Supplement (Gibco), 1% penicillin-
streptomycin (Lonza), and 1% L-glutamine (Lonza) for no more than 8 passages. Human For-
skin Fibroblasts (HFF) (ATCC cell collection) cells were maintained in DMEM (Dulbecco's
modified Eagle's medium) (Lonza) supplemented with 10% (v/v) fetal bovine serum (Gibco),
1% penicillin-streptomycin (Lonza), and 1% L-glutamine (Lonza) for no more than 30 pas-
sages. Both of the cells were incubated at 37°C in a humidified environmental incubator sup-
plemented with 5% CO2. Etoposide (Enzo) was used to induce apoptosis at 10 μM for 24 h.
The cells used in this study are non-transformed cells and represent two different important
cell types in diseases such as heart disease and cancer, namely fibroblast and endothelial cells.
In addition, these cells would be expected to have different sensitivities to hypoxia exposure.
Antibodies andWestern blotting
Cells were lysed in a RIPA lysis buffer (50 mM Tris, pH 8.0, 150 mMNaCl, 1% NP-40, 0.1%
SDS, 0.5% sodium deoxycholate, 250 mMNa3VO4, 10 mM NaF and protease inhibitor cocktail
tablet). Western blotting was carried out using the following antibodies: anti-HIF-1α (R&D
Systems #MAB1536, mouse monoclonal, 1:1000 dilution), anti-HIF-2α (Thermo Fisher Scien-
tific #PA1-16510, rabbit polyclonal, 1:1000 dilution), anti-HIF-1β (Cell Signaling Technology
#5537, rabbit polyclonal, 1:1000 dilution), anti-GLUT1 (glucose transporter 1) (Thermo Fisher
Scientific #RB-9052-P, rabbit polyclonal, 1:1000 dilution), anti-Glut3 (AnaSpec #53520, rabbit
polyclonal, 1:1000 dilution), anti-β-actin (Sigma #A5441, rabbit polyclonal, 1:5000 dilution),
anti-cleaved PARP [poly(ADP-ribose) polymerase] (Cell Signaling Technology #9541, rabbit
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polyclonal, 1:1000 dilution), anti-PHD2 (Bethyl #A300-322A, rabbit polyclonal, 1:1000 dilu-
tion), anti-PHD3 (Bethyl #A300-327A, rabbit polyclonal, 1:1000 dilution), anti-NDRG1 (Cell
Signaling Technology #9485, rabbit monoclonal 1:1000 dilution), anti-Cited-2 (Santa Cruz
Biotechnology #sc-25375, rabbit polyclonal 1:500 dilution) and hydroxylated P564-HIF-1α
(Cell Signaling Technology #3434, rabbit monoclonal 1:1000 dilution). All images are repre-
sentative of a minimum of three independent experiments, ranging from 3–6.
Western blot quantification
Western blots were analysed using ImageJ software to determine band intensity, normalised to
the loading control signal. Control conditions bands were set at 1, and treatments with Allopu-
rinol compared to control. Data is presented as the mean and standard deviation of a minimum
of three independent experiments.
Hypoxia inductions and MG132 treatment
Cells were incubated at 1% oxygen in an INVIVO2 300 hypoxia workstation (Ruskinn). Cell
extracts for protein and RNA were performed inside the workstation to avoid re-oxygenation.
For hypoxia-mimetic conditions, cells were treated with 200 μM desferrioxamine (DFX,
Sigma) for 16 h prior to harvest using passive lysis buffer (Promega). MG132 (Merck Biosci-
ences) at 20 μMwas added 3 h prior to cell harvesting.
qPCR and PCR sequences
Total RNA extraction was performed using PeqGOLD Total RNA Kit (Peqlab) according to
the manufacturer's directions. RNA was converted to cDNA using QuantiTect Reverse Tran-
scription Kit (Qiagen). Relative quantitative RT-PCR assay was performed using cDNA tem-
plates amplified using specific primer sets and the Brilliant II SYBR Green qPCR Low ROX
Master Mix (Stratagene) according to the manufacturer's instructions. Amplification and de-
tection were performed using a Stratagene Mx3005P detection system. During amplification, a
detector monitored real-time PCR amplification by quantitative analysis of the fluorescence
emissions. Sample values obtained with specific primer sets were normalized to β-actin primer
set values. The PCR primer sequences used were as described previously [13]. Data analysis
was provided by the MxPro software (Stratagene/Agilent) based on the @@CT method. All data
presented in the mean of a minimum of three independent experiments performed
in duplicate.
Endothelial Tube formation assay
Angiogenesis slides (Ibidi) were coated with 10 μL Growth Factor Reduced Matrigel (Becton
Dickinson) per well and incubated for 30 min at 37°C. HUVEC were detached by trypsin and
adjusted to 100000 cells per ml with allopurinol at 0, 10, 100, and 1000 μg/ml. Cell suspension
(50 μL per well) was seeded into each well. After 24 h, cells were photographed and analysed by
ImageJ. All experiments were carried out in triplicate.
Statistical analysis
ANOVA and Student’s t-tests were performed to determine differences among groups and p
values were calculated. Data were expressed as mean values ± Standard Deviation of at least
three independent experiments (SigmaPlot). Statistical significance was defined as  P<0.050,
 P<0.01,  P<0.001.
Allopurinol and the HIF System
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Results
Characterisation of the response in HFF and HUVEC cells under
hypoxia
Since hypoxia is a major feature of cardiovascular disease [14], we aimed to characterise the
hypoxia response in two different cellular backgrounds. Hypoxia-inducible factors and in partic-
ular, the oxygen labile 1-α subunit (HIF-1α) are principle regulators of cellular hypoxia adapta-
tion [15]. However, different cell types may have different kinetics of the hypoxia response. To
understand how two different cellular systems respond to hypoxia we performed a time course
analysis for protein expression of HIF subunits and a selection of its targets in HFF and
HUVEC in hypoxia. HFF and HUVEC were incubated in 1% oxygen from 0 to 24 hours. Both
HFF and HUVEC responded to hypoxia by inducing HIF-1α protein levels (Fig 1A). While
HUVEC cells start to reduce HIF-1α levels around 2 hours, in HFF cells this was not observed.
For both types of cells, the accumulation of HIF-2α protein was relatively slower than the accu-
mulation of HIF-1α, as it has been seen for cancer cells [16]. HIF-1β protein levels remained rel-
atively constant, as HIF-1β is not sensitive to oxygen availability (Fig 1A).
Under normoxic conditions, the degradation of HIF-α is triggered by the hydroxylation of
specific proline residues by prolyl hydroxylases 1, 2 and 3 (PHD1, 2 and 3), which create a
binding site for the Von Hippel-Lindau tumour-suppressor protein [17]. Since PHDs have an
absolute requirement for molecular oxygen, under hypoxia PHDs activity is reduced, and the
degradation of HIF-α is blocked. This in turn, capacitates HIF-α transcription to activate hyp-
oxia-responsive target genes [18]. Several HIF-dependent targets were analysed in HFF and
HUVEC cells following hypoxia (Fig 1A). Both PHD2 and PHD3 protein levels were increased
after prolonged hypoxia. This increase is likely responsible for the reduction in HIF-1α protein
levels in HUVEC cells after 8 hours (Fig 1A). In addition, Glut3 was also induced in both cell
lines, although the kinetics of activation was different for HFF and HUVEC cells.
Finally, the levels of Cited2 and NDRG1 proteins were also analysed. These genes can be ac-
tivated by both HIF-1α and HIF-2α or HIF-2α alone [19, 20]. Interestingly, these genes were
only induced following hypoxia in the HFF cells but not in HUVEC cells (Fig 1A). This analysis
revealed the similarities and differences between the two cellular backgrounds, and highlighted
the differential activation of the HIF system under hypoxia.
Allopurinol alters normoxic HIF responses in HFF but not HUVEC cells
To determine if allopurinol can regulate basal or normoxic HIF levels, we performed a dose de-
pendent response analysis in both HFF and HUVEC cells. Cells were treated with increasing
amounts of allopurinol for 17 hours under normoxia conditions. To observe HIF-α under nor-
moxic conditions, we exposed our western blots much longer compared to hypoxic conditions,
as it can be seen when comparing Fig 1A with Fig 1B. Allopurinol treatment resulted in dose-
dependent effects in both of the cell types analysed. In HFF, allopurinol treatment at 1000 μg/
ml substantially reduced HIF-1α and HIF-2α protein expression, while HIF-1β expression was
mostly unaffected by allopurinol treatment (Fig 1B).
To determine if the reduction of basal HIF levels was altering the expression of HIF-depen-
dent target genes, we analysed the levels of several HIF targets at the protein level, following a
dose dependent treatment with allopurinol (Fig 1B). The analyses of the relationship between
HIF targets at protein levels and dose-dependent increases of alloprinol revealed a differential
response in HFF and HUVEC cells. While in HFF, treatment with a higher dose of allopurinol
resulted in reduced levels of the majority of HIF dependent target genes analysed, in HUVEC
cells we could not detect any alteration in the proteins we have analysed. Analysis of the levels
Allopurinol and the HIF System
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Fig 1. Increasing doses of Allopurinol reduce HIF-1α levels in normoxic HFFs and HUVEC cells. A.
Characterisation of HFF and HUVEC response to hypoxia. Cells were exposed to hypoxia (1% oxygen) for
the indicated periods of time. At the end of incubation, protein levels were determined in whole cell extracts by
immunoblot analysis using the depicted antibodies. B. Cells were treated with Allopurinol at 10, 100 and
1000 μg/ml for 17 hours. Then the cells were lysed for assessment of the indicated protein levels. Cells were
Allopurinol and the HIF System
PLOSONE | DOI:10.1371/journal.pone.0123649 April 1, 2015 5 / 12
of cleaved PARP, a marker for apoptosis, indicated that allopurinol treatment was not inducing
apoptosis in either of the cellular backgrounds analysed (Fig 1B).
This analysis revealed that HFF and HUVEC cells not only have different kinetics in their
response to hypoxia but also have different sensitivity to allopurinol treatment under
normoxic conditions.
Allopurinol treatment reduces hypoxic HIF-1α levels in HFF and HUVEC
cells but only partially affects HIF responses
Since HIF transcription factors are mostly active in hypoxia, we next determined how allopuri-
nol affects the HIF response in hypoxia. HIF-1α levels were reduced with treatment with high
doses of allopurinol in both cell types (Fig 2A). HIF-2α and HIF-1β levels were not altered sig-
nificantly by treatment with allopurinol in hypoxia, opposite to the effects seen in normoxia. In
addition, when HIF-dependent targets were analysed under these conditions, only high doses
of allopurinol, resulted in reduced HIF targets expression in hypoxia, but once again only in
HFF cells but not in HUVECs (Fig 2A). These results again, support the hypothesis that
HUVEC cells are less sensitive to allopurinol treatment than HFFs when HIF-dependent re-
sponses are analysed.
To determine if allopurinol treatment affects HIF levels by interfering with their mRNA, we
next measured HIF-1α and HIF-2α transcript levels by qPCR. Our analysis revealed that allo-
purinol has no significant effect in the levels of HIF-1α or HIF-2αmRNA in normoxia in both
cell lines tested (Fig 2B). In hypoxia, we could only detect statistical differences in the levels of
HIF-1α and HIF-2α in HFF cells following allopurinol treatment, while HUVEC cells were
only altered with higher doses (Fig 2B). Of note, although statistically significant, the mRNA
changes observed following treatment with allopurinol are only minimal, and as such, we
would not expect these changes to be biologically significant, as it is observed in the
protein level.
Allopurinol alters HIF levels independently of PHD function
To address the involvement of PHDs in the effects seen after allopurinol treatment, we used
desferrioxamine (DFX), an iron chelator, to inhibit PHD activity and thus stop the PHD de-
pendent HIF-1α degradation pathway (Fig 3A). Both HFF and HUVEC cells showed a robust
up regulation of HIF-1α protein following DFX treatment (Fig 3A). Interestingly, allopurinol
treatment resulted in a dose-dependent reduction of HIF-1α protein levels in both cell lines.
These results suggest that in HUVEC cells, allopurinol treatment will also result in reduced
HIF-1α levels, but that these cells require a more dramatic reduction in oxygen to activate the
HIF pathway. In addition, it demonstrates that allopurinol induced HIF-1μ reduction is inde-
pendent of PHD activity.
To fully demonstrate that allopurinol is not increasing the PHD-dependent degradation
pathway, we used MG132, a cell-permeable proteasome inhibitor in the absence or presence of
allopurinol treatment (Fig 3B). As expected, MG132 treatment resulted in stabilisation of HIF-
1α protein levels in both cell types (Fig 3B). However, in the presence of allopurinol, HIF-1α
levels were not fully restored by MG132 treatment. In addition, we also observed reduced levels
of hydroxylated HIF-1α, supporting our findings that PHD levels are reduced by allopurinol
treated with Etoposide (Etop) for 24 hours under normoxia. H-cells exposed to 1%O2 for 16 hours. HIF-1α
levels were quantified using ImageJ software and graph depicts mean and standard deviation of a minimum
of three independent experiments. Anova t-test was performed and p values calculated as follows: *p<0.05;
**p<0.01; ***p<0.001.
doi:10.1371/journal.pone.0123649.g001
Allopurinol and the HIF System
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Fig 2. Increasing doses of Allopurinol reduce HIF-1α levels in hypoxic HFFs, without changing HIF mRNA levels but have reduced effect in HUVEC
cells. A. Cells were pre-treated with Allopurinol at 10, 100 and 1000 μg/ml for 5, 30 and 60 minutes then were incubated in 1% oxygen for 16 hours. The cells
were lysed for assessment of the indicated proteins. HIF-1α levels were quantified using ImageJ software and graph depicts mean and standard deviation of
a minimum of three independent experiments. Anova t-test was performed and p values calculated as follows: *p<0.05; **p<0.01; ***p<0.001. B. HIF-1α
and HIF-2αmRNA levels were analysed by quantitative PCR in HFF and HUVEC cells. Graph depicts the mean and standard deviation of a minimum of
three independent experiments performed in duplicate. Anova t-test was performed and p values calculated as follows: *p<0.05; **p<0.01; ***p<0.001.
doi:10.1371/journal.pone.0123649.g002
Allopurinol and the HIF System
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treatment (Fig 3B). Taken together, these data indicate that allopurinol treatment alters HIF
levels via a PHD-independent pathway.
Fig 3. Allopurinol reduces HIF-1α levels independent of PHD function. A. Cells were pre-treated with
Allopurinol at 10 and 1000 μg/ml for 60 minutes and then were incubated in 1% oxygen or treated with
200 μMDFX for 16 hours. Whole cell lysates were analysed by immunoblot using the indicated antibodies. B.
Cells were pre-treated with Allopurinol at 1000 μg/ml for 60 minutes and then were incubated with 20μM
MG132 for 3 hours. Whole cell lysates were analysed by immunoblot using the indicated antibodies. HIF-1α
levels were quantified using ImageJ software and graph depicts mean and standard deviation of a minimum
of three independent experiments. Anova t-test was performed and p values calculated as follows: *p<0.05;
**p<0.01; ***p<0.001.
doi:10.1371/journal.pone.0123649.g003
Allopurinol and the HIF System
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Allopurinol reduces angiogenesis traits of HUVEC cells
Endothelial cells are important in blood vessels and, as such, can be used as an in vitromodel
of angiogenesis [21]. To determine if allopurinol alters HUVEC cells ability to produce endo-
thelial tubes, we treated these cells with increasing concentrations of allopurinol and measured
characteristics of this model (Fig 4). While the low dose of allopurinol, had no effect on total
tube length, increasing doses of allopurinol resulted in a progressive reduction in the tube
length (Fig 4). These results suggest that allopurinol can alter angiogenic potential of
endothelial cells.
Discussion
Here, we investigated two different cellular models and how they respond to hypoxia and treat-
ment with allopurinol. Endothelial cells have a shorter period of hypoxia adaptation than HFF
cells, indicated by the timing of HIF-1α activation and degradation. This is not surprising as
endothelial cells are exposed to much higher oxygen levels than most tissues and as such need
a quicker adaptation period to hypoxia, in order to survive [22]. We found that overall HFF
cells are more sensitive to allopurinol treatment both in normoxia and hypoxia, when com-
pared with HUVEC cells. Nevertheless, HUVEC cells were affected by higher doses of allopuri-
nol when analysed for the ability to produce endothelial tubes in vitro. Furthermore, we
observed that allopurinol effects over the HIF system were independent of PHD function and
HIF subunit mRNA levels. Interestingly, the reduction observed in HIF-1α levels following al-
lopurinol treatment was not reversed when the proteasome was inhibited. This suggests that al-
lopurinol alters either HIF protein translation rates or proteasomal-independent
degradation pathways.
Allopurinol was recently shown to control mTOR activity [23], a master regulator of protein
synthesis in the cell [24]. mTOR is a known regulator of HIF-1α translation [25, 26], and as
such could provide an explanation for our finding of reduced HIF-1α levels in the presence of
allopurinol, even with the DFX treatment, that completely inhibits PHD function in cells. Fur-
ther research, analysing mTOR activity following treatment with allopurinol in these cells, as
Fig 4. Allopurinol alters angiogenic traits of HUVEC in an in vitro endothelial tube model.Cells were treated with Allopurinol at 0, 10, 100, 1000 μg/ml,
and analysed at 24 hours. A, control group without Allopurinol. B, 10 μg/ml Allopurinol. C, 100 μg/ml Allopurinol. D, 1000 μg/ml Allopurinol. Graph depicts
mean and standard deviation of tube length measures in a minimum of three independent experiments performed in triplicate. Anova t-test was performed
and p values calculated as follows: *p<0.05; **p<0.01; ***p<0.001.
doi:10.1371/journal.pone.0123649.g004
Allopurinol and the HIF System
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well as activation marks for AMPK, a master regulator of mTOR [27], would be required to an-
swer this particular question.
While mTOR regulation by allopurinol is a possible and viable explanation for the reduction
observed in HIF-1α, alternatives mechanisms could also be involved. Recently, proteasomal-in-
dependent degradation pathways have been described for HIF-1α, including lysosomal and
autophagy [28]. While there is some evidence that allopurinol can prevent lysosome enzyme
release in disease conditions, the precise analysis of lysosomal degradation pathways in the
presence of this drug has not yet been accessed. Similarly, the effects of allopurinol of the pro-
cess of autophagy have not been investigated yet, making any assumption concerning the in-
volvement of these pathways in the effects observed in this study difficult to document.
Endothelial cells are an essential component of blood vessels and their functional integrity
[29]. One interesting finding from this study, was the reduction in angiogenic traits of
HUVECs when treated with higher doses of allopurinol. Neo-angiogenesis is a key feature of
most solid tumours, and it thought to contribute to the tumour growth and metastatic poten-
tial, due to the leakiness of the vessels made [30]. Interestingly, allopurinol has been used in
cancer, as a way to block common side effects of routinely used chemotherapies [31, 32]. How-
ever, no report exists on the effects of allopurinol in the process of angiogenesis or vessel nor-
malisation. This would be an interesting aspect to investigate, given our results with HUVEC
cells, in particular in highly angiogenesis dependent cancers such as glioblastoma or breast can-
cer. Allopurinol could thus be a substitute for anti-angiogenic therapy that in recent years has
proven to be relatively unsuccessful, with the cancer finding alternative routes to induce the
process [33]. This may also lend support to the hypothesis that allopurinol may have a sparing
effect on molecular oxygen as seen in clinical trials of patients with coronary artery disease
where allopurinol significantly prolonged time to the development of electrocardiographic is-
chemic changes on an exercise tolerance test [4].
Overall, allopurinol did not change cell viability, despite changing HIF levels in hypoxia. It
is possible that the HIF levels that remain are sufficient to maintain viability of cells. It would
be interesting to test if under hypoxic conditions, in the presence of allopurinol, additional che-
motherapeutic or even radiotherapy would have a higher therapeutic index. Additional work is
thus necessary to answer these questions.
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